Literature DB >> 18446054

Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.

Kyung Hwan Jeong1, Tae Won Lee, Chun Gyoo Ihm, Sang Ho Lee, Ju Young Moon.   

Abstract

Genetic polymorphisms may be linked to inter-individual differences in erythropoietin (EPO) resistance. We investigated the -511C/T polymorphism of the IL-1B gene and the I/D polymorphism of the ACE gene for any association with EPO resistance index (ERI) in maintenance hemodialysis patients (n=167). Because EPO responsiveness is multi-factorial, we also included other possible influences (age, sex, time on dialysis, ACE inhibitor or angiotensin receptor blocker use, ferritin, transferrin saturation, intact PTH, high sensitivity C-reactive protein, albumin, Kt/V, and presence of diabetes mellitus) on ERI in our analyses. Multiple regression analysis showed significant association of the IL-1B-511CC and ACE DD polymorphisms with ERI (P=0.038 and P=0.004 in the recessive model, respectively). The combination (C) of alleles of two loci showed that C1 (I-T) was significantly associated with ERI in the co-dominant and recessive models (P=0.005 and P=0.0001, respectively). Subjects who did not carry C1 showed significantly decreased ERI (10.10+/-5.15 IU/kg weight/g hemoglobin) compared to other study subjects (C1/C1 and C1/-; 12.97+/-4.90 and 15.12+/-7.43 IU/kg weight/g hemoglobin, respectively). Our study indicates that the IL-1B-511C/T and ACE I/D polymorphisms may be useful genetic markers of EPO requirement in hemodialysis patients. These findings might also provide a new perspective on therapeutic approaches to the treatment of end stage renal disease patients with anemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446054      PMCID: PMC2679299          DOI: 10.3858/emm.2008.40.2.161

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  23 in total

1.  Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.

Authors:  N Muirhead; A B Hodsman
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

Review 2.  Erythropoietin resistance in the treatment of the anemia of chronic renal failure.

Authors:  Anumeet Priyadarshi; Joseph I Shapiro
Journal:  Semin Dial       Date:  2006 Jul-Aug       Impact factor: 3.455

Review 3.  Treatment of renal anemia with recombinant human erythropoietin.

Authors:  R M Schaefer; W H Hörl; S G Massry
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

4.  [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients].

Authors:  M Hatano; T Yoshida; T Mimuro; N Kimata; K Tsuchiya; T Sanaka; H Nihei
Journal:  Nihon Jinzo Gakkai Shi       Date:  2000-10

5.  Case management of the anemic patient. Epoetin alfa: focus on inflammation and infection.

Authors:  K E Schardin
Journal:  ANNA J       Date:  1990-12

6.  Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1beta-511 promoter gene and raised levels of interleukin-1beta and interleukin-18.

Authors:  C P J Maury; M Liljeström; K Laiho; S Tiitinen; K Kaarela; M Hurme
Journal:  J Intern Med       Date:  2004-08       Impact factor: 8.989

7.  Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy.

Authors:  Angela C Cooper; Ashraf Mikhail; Mark W Lethbridge; D Michael Kemeny; Iain C Macdougall
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

8.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.

Authors:  Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

10.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

View more
  8 in total

1.  An alternative method for genotyping of the ACE I/D polymorphism.

Authors:  Kimberly L Glenn; Zhi-Qiang Du; Joey C Eisenmann; Max F Rothschild
Journal:  Mol Biol Rep       Date:  2008-07-13       Impact factor: 2.316

2.  Resistance of dialyzed patients to erythropoietin.

Authors:  Michelle Teodoro Alves; Sandra Simone Vilaça; Maria das Graças Carvalho; Ana Paula Fernandes; Luci Maria Sant'Ana Dusse; Karina Braga Gomes
Journal:  Rev Bras Hematol Hemoter       Date:  2015-02-17

3.  Effect of erythropoietin on primed leucocyte expression profile.

Authors:  Mirko Pesce; Paolo Felaco; Sara Franceschelli; Lorenza Speranza; Alfredo Grilli; Maria Anna De Lutiis; Alessio Ferrone; Vittorio Sirolli; Mario Bonomini; Mario Felaco; Antonia Patruno
Journal:  Open Biol       Date:  2014-06       Impact factor: 6.411

4.  Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population.

Authors:  Chao Zhang; Zhongxing Li; Qiang Cao; Chao Qin; Hongzhou Cai; Hai Zhou; Jian Qian; Liangjun Tao; Xiaobing Ju; Changjun Yin
Journal:  J Biomed Res       Date:  2014-08-11

5.  ACE gene polymorphism and its association with serum erythropoietin and hemoglobin ‎in Iraqi hemodialysis patients.

Authors:  Mohanad Yasir Al-Radeef; Hayder Adnan Fawzi; Ali Abdulmajid Allawi
Journal:  Appl Clin Genet       Date:  2019-07-01

6.  The role of genetic polymorphisms in STIM1 and ORAI1 for erythropoietin resistance in patients with renal failure.

Authors:  Chih-Chin Kao; Henry Sung-Ching Wong; Yu-Jia Wang; Wan-Hsuan Chou; Dyah Aryani Perwitasari; Mai-Szu Wu; Wei-Chiao Chang
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

7.  Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism.

Authors:  Abdulrahman Hamdan Almaeen; Gomaa Mostafa-Hedeab
Journal:  Pharmgenomics Pers Med       Date:  2021-08-27

Review 8.  Opportunities and Challenges for Genetic Studies of End-Stage Renal Disease in Canada.

Authors:  Vinusha Kalatharan; Mathieu Lemaire; Matthew B Lanktree
Journal:  Can J Kidney Health Dis       Date:  2018-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.